Gene therapy trial targets Parkinson's at its genetic root

NCT ID NCT07011771

Terminated Disease control Sponsor: Capsida Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a one-time gene therapy called CAP-003 in adults with Parkinson's disease caused by a GBA1 gene mutation. The goal is to see if it is safe and if it can help control the disease. Participants receive a single IV infusion and are monitored for two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBA1 PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

GBA1-related Parkinson disease, susceptibility Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBA1 PARKINSON DISEASE

Contacts and locations

Show contact details

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Inland Northwest Research

Spokane, Washington, 99202, United States
New York Presbyterian Hospital-Columbia University Medical Center

New York, New York, 10032, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States